Physician profile
John A Bertelson
NPI 1215959697
$312,915.22
in general payments reported to CMS, 2019-2025
36 companies · $111K in 2025
The $111K reported for 2025 was more than what 98% of Behavioral Neurology & Neuropsychiatry providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,836 · 2020: $4,366 · 2021: $23K · 2022: $1,187 · 2023: $39K · 2024: $133K · 2025: $111K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $171K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $22K · Travel and Lodging: $19K · Food and Beverage: $8,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $170,570.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,950.00 |
| Consulting Fee | $22,122.50 |
| Travel and Lodging | $18,617.82 |
| Food and Beverage | $8,606.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $246,530.08 | 2019-2025 | |
| Lilly USA, LLC | $33,395.65 | 2022-2025 | Kisunla, Amyvid |
| Biogen, INC. | $26,374.29 | 2019-2025 | Leqembi, Aduhelm |
| Onmark, INC. | $1,400.00 | 2024 | |
| Corium, LLC | $1,133.82 | 2022-2023 | Adlarity |
| Janssen Pharmaceuticals, INC | $554.15 | 2022-2025 | Spravato |
| Lundbeck LLC | $553.09 | 2021-2025 | Rexulti, Brintellix |
| Acadia Pharmaceuticals INC | $482.16 | 2021-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $447.49 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $436.88 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $357.90 | 2021-2025 | Rexulti, Abilify Mycite |
| Axsome Therapeutics, INC. | $189.27 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $157.29 | 2021-2025 | Trintellix |
| Abbvie INC. | $135.29 | 2021-2025 | |
| Ge Healthcare | $110.40 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $93.48 | 2024 | Uplizna |
| Emd Serono, INC. | $69.84 | 2019-2023 | |
| Alkermes, INC. | $64.96 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $50.65 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.76 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $38.95 | 2023 | Quviviq |
| Grifols USA, LLC | $37.41 | 2019 | |
| Jazz Pharmaceuticals INC. | $36.50 | 2021 | |
| Avanir Pharmaceuticals, INC. | $30.40 | 2022 | |
| Life Molecular Imaging Ltd | $27.20 | 2023 | Neuraceq |
| Merz North America, INC. | $23.54 | 2020 | |
| Almatica Pharma LLC | $22.44 | 2021 | |
| Ucb, INC. | $19.93 | 2019 | |
| Merck Sharp & Dohme LLC | $19.36 | 2022 | |
| Abbott Laboratories | $19.31 | 2023 | Proclaim |
| Alexion Pharmaceuticals, INC. | $18.13 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.14 | 2025 | Caplyta |
| Alfasigma USA, INC. | $14.78 | 2022 | |
| Bausch Health US, LLC | $14.68 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bertelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.